(HealthDay)—From 2009 to 2018, there was an increase in the incidence of nonalcoholic fatty liver disease (NAFLD) among children, although many still remain undiagnosed, according to a study published online Nov. 19 in ...
Nov 19, 2020
0
2
A novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of acute pancreatitis. sHTG ...
Mar 9, 2023
0
31
(HealthDay)—Most Medicare fee-for-service beneficiaries with dyslipidemia who initiate statins undergo baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) testing, according to a study published ...
Jul 18, 2016
0
0
In a study published in the journal of Genes & Diseases, a team of researchers from Chonnam National University and the Korea Research Institute of Bioscience and Biotechnology unveiled important insights into liver injury ...
Sep 14, 2023
0
1
In children in the US and UK, a sudden increase in the number of cases of severe acute hepatitis of unknown causes (SAHUC) and pediatric acute liver failure was reported between October 2021 and May 2022. As of June 22, 2022, ...
Jul 19, 2022
0
16
(HealthDay)—Childhood adiposity is associated with increased odds of nonalcoholic fatty liver disease (NAFLD), according to a study published online March 29 in Pediatrics.
Mar 29, 2017
0
1
A new postage stamp-sized, paper-based device could provide a simple and reliable way to monitor for liver damage at a cost of only pennies per test, say researchers at Beth Israel Deaconess Medical Center (BIDMC) and Diagnostics ...
Sep 19, 2012
0
0
(HealthDay)—Turalio (pexidartinib) capsules have been approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT), the U.S. Food and Drug Administration announced.
Aug 5, 2019
0
3
(HealthDay) -- Serum levels of di(2-ethylhexyl) phthalate (DEHP) are increased in obese versus nonobese children, according to a study presented at the annual meeting of The Endocrine Society, held from June 23 to 26 in Houston.
Jun 25, 2012
0
0
Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic ...
Apr 23, 2015
0
5
